Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Evercore ISI Group Upgrades Sarepta Therapeutics to Outperform, Lowers Price Target to $179

Author: Benzinga Newsdesk | August 08, 2024 09:22am
Evercore ISI Group analyst Gavin Clark-Gartner upgrades Sarepta Therapeutics (NASDAQ:SRPT) from In-Line to Outperform and lowers the price target from $185 to $179.

Posted In: SRPT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist